

NOS2B (C-12): sc-165125

BACKGROUND

Nitric oxide (NO) has a broad range of biological activities and has been implicated in signaling pathways in phylogenetically diverse species. Nitric oxide synthases (NOSs), the enzymes responsible for synthesis of NO, contain an N-terminal oxygenase domain and a C-terminal reductase domain. NOS activity requires homodimerization as well as three cosubstrates (L-arginine, NADPH and O₂) and five cofactors or prosthetic groups (FAD, FMN, calmodulin, tetrahydrobiopterin and heme). Several distinct NOS isoforms have been described and been shown to represent the products of three distinct genes. NOS2B (NOS type II B) is a 79 amino acid protein that is encoded by a gene located on human chromosome 17p11.2. Chromosome 17 comprises over 2.5% of the human genome and encodes over 1,200 genes.

REFERENCES

1. Nathan, C. and Xie, Q.W. 1994. Nitric oxide synthases: roles, tolls, and controls. *Cell* 78: 915-918.
2. Schmidt, H.H.H.W. and Walter, U. 1994. NO at work. *Cell* 78: 919-925.
3. Marietta, M.A. 1994. Nitric oxide synthase: aspects concerning structure and catalysis. *Cell* 78: 927-930.
4. Heiss, L.N., Lancaster, J.R. Jr., Corbett, J.A., and Goldman, W.E. 1994. Epithelial autotoxicity of nitric oxide: role in the respiratory cytopathology of pertussis. *Proc. Natl. Acad. Sci. USA* 91: 267-270.
5. Farias-Eisner, R., Sherman, M.P., Aeberhard, E. and Chaudhuri, G. 1994. Nitric oxide is an important mediator for tumoricidal activity *in vivo*. *Proc. Natl. Acad. Sci. USA* 91: 9407-9411.
6. Kamijo, R., Harada, H., Matsuyama, T., Bosland, M., Gerecitano, J., Shapiro, D., Le, J., Im, K.S., Kimura, T., Green, S., Mak, T.W., Taniguchi, T. and Vilcek, J. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. *Science* 263: 1612-1615.
7. Bukrinsky, M.E., Nottet, H.S., Schmidt-mayerova, N., Dubrovsky, L., Flanagan, C.R., Mullins, M.E., Lipton, S.A. and Gendelman, H.E. 1995. Regulation of nitric oxide synthase activity in human immuno-deficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. *J. Exp. Med.* 181: 735-745.

CHROMOSOMAL LOCATION

Genetic locus: NOS2B (human) mapping to 17p11.2.

SOURCE

NOS2B (C-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of NOS2B of human origin.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-165125 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

NOS2B (C-12) is recommended for detection of NOS2B of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); may cross-react with NOS2.

Molecular Weight of NOS2B: 10 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.